James William Rogers Sells 31,780 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 31,780 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $82.33, for a total transaction of $2,616,447.40. Following the completion of the sale, the chief financial officer now directly owns 189,320 shares of the company’s stock, valued at $15,586,715.60. This represents a 14.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

James William Rogers also recently made the following trade(s):

• On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The stock was sold at an average price of $67.57, for a total transaction of $588,669.84.
• On Monday, December 16th, James William Rogers sold 1,468 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total value of $59,057.64.
• On Wednesday, December 11th, James William Rogers sold 83,025 shares of Tempus AI stock. The shares were sold at an average price of $42.30, for a total value of $3,511,957.50.

Tempus AI Price Performance

Shares of TEM opened at $76.72 on Friday. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock has a 50 day moving average of $49.75 and a 200 day moving average of $51.44.

Analyst Ratings Changes

TEM has been the subject of several research analyst reports. Piper Sandler reiterated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. TD Cowen reaffirmed a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Bank of America lifted their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Wolfe Research initiated coverage on Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, Loop Capital dropped their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $58.55.

Hedge Funds Weigh In On Tempus AI

Large investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its stake in Tempus AI by 13.2% in the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock worth $80,000 after purchasing an additional 278 shares in the last quarter. First Horizon Advisors Inc. bought a new stake in Tempus AI during the third quarter valued at approximately $30,000. Geode Capital Management LLC grew its position in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares in the last quarter. Operose Advisors LLC bought a new stake in Tempus AI in the 4th quarter worth approximately $25,000. Finally, Prestige Wealth Management Group LLC boosted its stake in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.